Alberto Restrepo

TL;DR: BST-CarGel treatment resulted in greater lesion filling and superior repair tissue quality compared with microfracture treatment alone, and clinical benefit was equivalent between groups at twelve months, and safety was similar.

TL;DR: BST-CarGel® was shown to be an effective mid-term cartilage repair treatment and resulted in sustained and significantly superior repair tissue quantity and quality over microfracture alone at 5 years.

TL;DR: Repair tissues revealed the potential of microfracture-based repair procedures to produce zonal CO resembling native articular cartilage structure, which could benefit the development of cartilage repair strategies intended to recreate functional collagen architecture.

TL;DR: In this article, a soluble polymer scaffold containing the polysaccharide chitosan, which is dispersed throughout uncoagulated whole blood, was developed to produce a physically stabilized blood clot that is more voluminous and adherent within a debrided cartilage lesion having access to bone marrow, thus improving existing bone marrow-stimulation procedures.

TL;DR: BST-CarGel was developed to produce a physically stabilized blood clot that is more voluminous and adherent within a debrided cartilage lesion having access to bone marrow, thus improving existing bone marrow-stimulation procedures and bringing a simple-yet-versatile treatment modality that applies scaffold-guided regenerative medicine to a potentially wide-ranging group of indications.